Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24554698 | 1.00 | SPHK1 (0.46) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL27303527 | 0.86 | SPHK1 (0.49) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL3448655 | 0.85 | SPHK1 (0.48) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL14496992 | 0.85 | SPHK1 (0.48) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL19481651 | 0.85 | SPHK1 (0.48) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL3451884 | 0.85 | SPHK1 (0.49) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL1776217 | 0.84 | SPHK1 (0.47) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL3450844 | 0.83 | SPHK1 (0.33) | SPHK1 | |
| SCHEMBL23341555 | 0.81 | SPHK1 (0.46) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL15319039 | 0.80 | SPHK1 (0.50) | SPHK1BRD4CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024133200-A1 | P2X3 RECEPTOR ANTAGONISTS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2024-06-27 | — | — | WO | disclosed |
| EP-4389746-A2 | P2X3 RECEPTOR ANTAGONISTS | Recordati Industria Chimica E Farmaceutica SPA (IT) | 2024-06-26 | — | — | EP | disclosed |
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1695961-A1 | UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | SPHK1 3531/4885BRD4 1814/4885CHRM2 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.